Cipla has launched an innovative combination of 3 HIV/AIDS drugs, Viraday that needs to be taken just once a day for effective treatment. Cipla has launched an innovative combination of 3 HIV/AIDS ...

Umang Vohra to Nimura: "In the case of tariff barriers, generics companies are likely to be more selective, focusing on high-value opportunities including 'first to file'." The Managing Director ...

On Tuesday, Jefferies analyst Alok Dalal increased the price target for Cipla (NSE:CIPL) Ltd. (CIPLA:IN) shares to INR1,580, up from INR1,560, while maintaining a Hold rating on the stock.